PROCEPT BioRobotics (PRCT) Competitors

PROCEPT BioRobotics (NASDAQ:PRCT) and Atrion (NASDAQ:ATRI) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, earnings, risk, community ranking, institutional ownership, profitability and dividends.

Does the MarketBeat Community prefer PRCT or ATRI?

Atrion received 101 more outperform votes than PROCEPT BioRobotics when rated by MarketBeat users. However, 62.22% of users gave PROCEPT BioRobotics an outperform vote while only 55.13% of users gave Atrion an outperform vote.

Company	Underperform	Outperform
PROCEPT BioRobotics	Outperform Votes 28 62.22%	Underperform Votes 17 37.78%
Atrion	Outperform Votes 129 55.13%	Underperform Votes 105 44.87%

Do institutionals & insiders hold more shares of PRCT or ATRI?

89.5% of PROCEPT BioRobotics shares are held by institutional investors. Comparatively, 66.2% of Atrion shares are held by institutional investors. 17.4% of PROCEPT BioRobotics shares are held by insiders. Comparatively, 22.8% of Atrion shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Do analysts prefer PRCT or ATRI?

PROCEPT BioRobotics presently has a consensus price target of $61.20, suggesting a potential downside of 4.26%. Given PROCEPT BioRobotics' higher probable upside, research analysts clearly believe PROCEPT BioRobotics is more favorable than Atrion.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PROCEPT BioRobotics	0 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	3.00
Atrion	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	N/A

Is PRCT or ATRI more profitable?

Atrion has a net margin of 10.60% compared to PROCEPT BioRobotics' net margin of -66.12%. Atrion's return on equity of 7.75% beat PROCEPT BioRobotics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PROCEPT BioRobotics	-66.12%	-41.35%	-27.92%
Atrion	10.60%	7.75%	7.12%

Which has preferable valuation and earnings, PRCT or ATRI?

Atrion has higher revenue and earnings than PROCEPT BioRobotics. PROCEPT BioRobotics is trading at a lower price-to-earnings ratio than Atrion, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PROCEPT BioRobotics	$136.19M	24.44	-$105.90M	-$2.12	-30.53
Atrion	$169.33M	4.79	$19.41M	$10.64	43.32

Which has more volatility & risk, PRCT or ATRI?

PROCEPT BioRobotics has a beta of 0.95, suggesting that its share price is 5% less volatile than the S&P 500. Comparatively, Atrion has a beta of 0.62, suggesting that its share price is 38% less volatile than the S&P 500.

Does the media prefer PRCT or ATRI?

In the previous week, Atrion had 11 more articles in the media than PROCEPT BioRobotics. MarketBeat recorded 14 mentions for Atrion and 3 mentions for PROCEPT BioRobotics. PROCEPT BioRobotics' average media sentiment score of 1.02 beat Atrion's score of 0.45 indicating that PROCEPT BioRobotics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
PROCEPT BioRobotics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Atrion	2 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Atrion beats PROCEPT BioRobotics on 10 of the 17 factors compared between the two stocks.